SCHEMBL716897

SCHEMBL716897

CCOC(=O)c1sc2ccncc2c1C

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDC7 O00311 10/20 0.49
DBF4 Q9UBU7 10/20 0.49
ALDH1A1 P00352 6/20 0.48
KMT2A Q03164 5/20 0.48
MEN1 O00255 3/20 0.48
MAPT P10636 3/20 0.48
HTT P42858 2/20 0.48
SMN1; SMN2 Q16637 2/20 0.48
HPGD P15428 2/20 0.48
LMNA P02545 2/20 0.47
KDM4E B2RXH2 2/20 0.45
RPS6KB1 P23443 1/20 0.45
CDK2 P24941 1/20 0.45
MAPKAPK2 P49137 1/20 0.45
GSK3B P49841 1/20 0.45
RPS6KA3 P51812 1/20 0.45
NPC1 O15118 1/20 0.45
POLB P06746 1/20 0.45
NFKB1 P19838 1/20 0.45
RAB9A P51151 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31750868 1.00 CDC7 (0.49) CDC7DBF4ALDH1A1KMT2AMEN1
SCHEMBL717339 0.89 ALDH1A1 (0.53) CDC7DBF4ALDH1A1KMT2AMEN1
SCHEMBL1215521 0.87 CDC7 (0.50) CDC7DBF4ALDH1A1KMT2AMEN1
SCHEMBL4724788 0.86 KDM4E (0.58) CDC7DBF4ALDH1A1KMT2AMEN1
SCHEMBL29513035 0.79 ALDH1A1 (0.64) ALDH1A1KMT2AMEN1MAPTSMN1; SMN2
SCHEMBL9025206 0.79 ALDH1A1 (0.64) ALDH1A1KMT2AMEN1MAPTSMN1; SMN2
SCHEMBL2176216 0.79 LIMK1 (0.45) CDC7DBF4ALDH1A1HTTHPGD
SCHEMBL1218547 0.79 KDM4E (0.52) CDC7DBF4ALDH1A1KMT2AMEN1
SCHEMBL30555073 0.79 KDM4E (0.52) CDC7DBF4ALDH1A1KMT2AMEN1
SCHEMBL24091065 0.79 KDM4E (0.52) CDC7DBF4ALDH1A1KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025264954-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS ALEXION PHARMACEUTICALS, INC. (US) 2025-12-26 WO disclosed
US-20230219974-A1 ANTHELMINTIC AZA-BENZOTHIOPHENE AND AZA-BENZOFURAN COMPOUNDS BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) 2023-07-13 US disclosed
CN-108570059-B Compound with PRMT5 inhibitory activity and preparation and application thereof 中国科学院上海药物研究所 2022-02-08 CN disclosed
US-20140329836-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2014-11-06 US disclosed
US-20140329836-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2014-11-06 US disclosed
US-20140329836-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2014-11-06 US disclosed
US-8624040-B2 Substituted hydroxamic acids and uses thereof MILLENNIUM PHARMACEUTICALS, INC. (US) 2014-01-07 US disclosed
US-8436043-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-05-07 US disclosed
US-20120270865-A2 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-10-25 US disclosed
US-20120053173-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-03-01 US disclosed
US-20110046157-A1 Substituted hydroxamic acids and uses thereof MILLENNIUM PHARMACEUTICALS, INC. (US) 2011-02-24 US disclosed
US-20110046157-A1 Substituted hydroxamic acids and uses thereof MILLENNIUM PHARMACEUTICALS, INC. (US) 2011-02-24 US disclosed
US-20110046157-A1 Substituted hydroxamic acids and uses thereof MILLENNIUM PHARMACEUTICALS, INC. (US) 2011-02-24 US disclosed
WO-2010151317-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2010-12-29 WO disclosed
WO-2010151317-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2010-12-29 WO disclosed
EP-2251326-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2010-11-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120053173-A1 HETEROCYCLIC COMPOUND SLC5A2, SLC5A1, IAPP CDC7 2704/4885DBF4 1432/4885ALDH1A1 504/4885
US-20140329836-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF HDAC6, HDAC5, HDAC1 CDC7 3079/4885DBF4 4738/4885ALDH1A1 1220/4885
US-20230219974-A1 ANTHELMINTIC AZA-BENZOTHIOPHENE AND AZA-BENZOFURAN COMPOUNDS TPMT, NAT1, HNMT CDC7 4130/4885DBF4 168/4885ALDH1A1 1114/4885
US-20120270865-A2 HETEROCYCLIC COMPOUND SLC5A2, SLC5A1, IAPP CDC7 2704/4885DBF4 1432/4885ALDH1A1 504/4885
US-20110046157-A1 Substituted hydroxamic acids and uses thereof HDAC6, HDAC5, HDAC1 CDC7 3079/4885DBF4 4738/4885ALDH1A1 1220/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.